Risankizumab in Severe Asthma - A Phase 2a, Placebo-Controlled Trial.
Christopher E BrightlingParameswaran NairDavid J CousinsRenaud LouisDave SinghPublished in: The New England journal of medicine (2021)
Risankizumab treatment was not beneficial in severe asthma. The time to the first asthma worsening was shorter and the annualized rate of asthma worsening was higher with risankizumab than with placebo. (Funded by AbbVie and Boehringer Ingelheim; ClinicalTrials.gov number, NCT02443298.).